Varespladib sodium (LY315920 sodium) is a potent and selective inhibitor of group IIA secretory phospholipase A2 (sPLA2), with an IC50 of 9 nM; it effectively inhibits sPLA2 activity in serum from various species including rat, rabbit, guinea pig, and human, with IC50 values of 8.1 nM, 5.0 nM, 3.2 nM, and 6.2 nM, respectively; it completely suppresses retinoic acid (RA)-induced MUC16 protein expression in HCjE cells at both 24 and 48 hours (100% inhibition at 24 h and 99% at 48 h); in vivo, it inhibits human sPLA2-induced thromboxane A2 (TXA2) release from guinea pig bronchoalveolar lavage (BAL) cells with an IC50 of 0.79 μM and shows consistent inhibition of sPLA2 activity in BAL fluid with an ED50 of 16.1 mg/kg.